PMID- 36263051
OWN - NLM
STAT- MEDLINE
DCOM- 20221021
LR  - 20230327
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 13
DP  - 2022
TI  - Atopy as an independent predictor for long-term patient and graft survival after 
      kidney transplantation.
PG  - 997364
LID - 10.3389/fimmu.2022.997364 [doi]
LID - 997364
AB  - BACKGROUND: Atopy is a genetic condition predisposing individuals to develop 
      immunoglobulin E (IgE) against common allergens through T-helper 2 (Th2) 
      polarization mechanisms. The impact of atopy on graft survival in solid organ 
      transplantation is unknown. METHODOLOGY: We analyzed 268 renal allograft 
      recipients from the Swiss Transplant Cohort Study, a prospective multicenter 
      cohort studying patients after solid organ transplantation, with a 9-year median 
      follow-up (IQR 3.0). We used the Phadiatop assay to measure IgE antibodies 
      against a mixture of common inhaled allergens (grass, tree, herbs, spores, 
      animals, and mites) to identify pre-transplantation atopic patients (>0.35 KU/L). 
      RESULTS: Of 268 kidney transplant recipients, 66 individuals were atopic (24.6%). 
      Atopic patients were significantly younger than non-atopic patients (49.6 vs 58.0 
      years old, P = 0.002). No significant difference was found for gender, cold/warm 
      ischemia time, preformed donor-specific antibodies (DSA), HLA mismatches, 
      induction and maintenance immunosuppressive therapy, CMV serostatus, or cause of 
      kidney failure. Patient and graft survival at ten years of follow-up were 
      significantly better in the atopic group, 95.2% versus 69.2% patient survival (P 
      < 0.001), and 87.9% versus 60.8% graft survival (P < 0.001), respectively. A 
      multivariate Cox analysis revealed that atopy predicted recipient and graft 
      survival independently of age and living donor donation. Finally, we found 
      similar rates of biopsy-proven acute cellular and antibody-mediated rejections 
      between atopic and non-atopic recipients. CONCLUSION: Atopy was associated with 
      better long-term patient and graft survival, independently of age and living 
      donor donation after kidney transplantation. Yet, atopy should not be used as a 
      predictor for acute rejection.
CI  - Copyright (c) 2022 Porret, Meier, Mikulic, Pascual, Aubert, Harr, Golshayan and 
      Muller.
FAU - Porret, Raphael
AU  - Porret R
AD  - Division of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois and 
      University of Lausanne, Lausanne, Switzerland.
FAU - Meier, Raphael P H
AU  - Meier RPH
AD  - Department of Surgery, University of Maryland School of Medicine, Baltimore, MD, 
      United States.
FAU - Mikulic, Josip
AU  - Mikulic J
AD  - Transplantation Center, Centre Hospitalier Universitaire Vaudois and University 
      of Lausanne, Lausanne, Switzerland.
FAU - Pascual, Manuel
AU  - Pascual M
AD  - Transplantation Center, Centre Hospitalier Universitaire Vaudois and University 
      of Lausanne, Lausanne, Switzerland.
FAU - Aubert, Vincent
AU  - Aubert V
AD  - Division of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois and 
      University of Lausanne, Lausanne, Switzerland.
FAU - Harr, Thomas
AU  - Harr T
AD  - Division of Immunology and Allergy, University Hospitals of Geneva, Geneva, 
      Switzerland.
FAU - Golshayan, Dela
AU  - Golshayan D
AD  - Transplantation Center, Centre Hospitalier Universitaire Vaudois and University 
      of Lausanne, Lausanne, Switzerland.
FAU - Muller, Yannick D
AU  - Muller YD
AD  - Division of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois and 
      University of Lausanne, Lausanne, Switzerland.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20221003
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
EIN - Front Immunol. 2023 Mar 08;14:1175484. PMID: 36969206
MH  - Humans
MH  - *Graft Survival
MH  - *Kidney Transplantation/adverse effects
MH  - Graft Rejection
MH  - Cohort Studies
MH  - Prospective Studies
MH  - Living Donors
MH  - Immunoglobulin E
PMC - PMC9574189
OTO - NOTNLM
OT  - atopy
OT  - graft survival
OT  - kidney
OT  - patient survival
OT  - rejection
OT  - survival
OT  - transplantation
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest. Open access funding provided by University of Lausanne.
EDAT- 2022/10/21 06:00
MHDA- 2022/10/22 06:00
PMCR- 2022/01/01
CRDT- 2022/10/20 02:53
PHST- 2022/07/18 00:00 [received]
PHST- 2022/09/15 00:00 [accepted]
PHST- 2022/10/20 02:53 [entrez]
PHST- 2022/10/21 06:00 [pubmed]
PHST- 2022/10/22 06:00 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2022.997364 [doi]
PST - epublish
SO  - Front Immunol. 2022 Oct 3;13:997364. doi: 10.3389/fimmu.2022.997364. eCollection 
      2022.